Kidney Disease Trial Results Will Debut in Denver
New research on IgA nephropathy treatments will be presented this October to update patients on evolving care.
Updated on Oct. 2, 2026 in Asthma
Live Poll
Do you trust that pharmaceutical patient support programs sufficiently lower costs for patients needing specialty treatments?
Vera Therapeutics is scheduled to present five abstracts, including final data from the ORIGIN 3 trial, at the ASN Kidney Week 2026 conference. The meeting will take place in Denver from October 22 to 25.
Why it matters
Understanding these clinical trial outcomes is essential for patients and clinicians evaluating new therapeutic options for IgA nephropathy, an autoimmune condition involving harmful B-cell activity. These presentations provide transparency regarding the efficacy and safety profile of emerging treatments.
Clinical trial data indicate that the BAFF and APRIL inhibitor TRUTAKNA is associated with a 32% infection rate, compared to 28% in the placebo arm. Researchers are continuing to assess these outcomes to confirm the medication's therapeutic impact.
The players
Vera Therapeutics
A biotechnology company focused on developing therapies for autoimmune and kidney diseases.
The details
TRUTAKNA functions as a soluble recombinant fusion protein designed to bind to BAFF and APRIL cytokines, which are proteins that drive the production of immune complexes by activated B cells. In IgA nephropathy, these complexes cause inflammation that damages the kidneys. The drug is delivered via a 150 mg once-weekly self-administered autoinjector.
Timeline
October 22, 2026: The ORIGIN 3 trial final efficacy analysis will be presented.
October 22-25, 2026: ASN Kidney Week 2026 occurs in Denver.
October 24, 2026: PIONEER trial results will be shared through a research poster.
Health Landscape
This development represents the latest step in the ongoing clinical research pipeline presented at the ASN Kidney Week conference, which serves as the primary forum for sharing advancements in nephrology. It builds upon the broader effort to move beyond supportive care toward targeted biological therapies for IgA nephropathy.
If you are managing IgA nephropathy, stay informed as these trial results are released to discuss the findings with your nephrologist. Understanding the distinction between common adverse effects, like infections or injection site reactions, is a helpful topic for your next care appointment.
The takeaway
Advancements in BAFF and APRIL inhibition represent a targeted shift in managing the immune-driven nature of autoimmune kidney disease. Patients should continue tracking new trial announcements and consult their healthcare team about how these emerging data points fit into their long-term care plan.
Further reading
For additional context on managing chronic inflammatory conditions, visit Asthma.
Live Poll
Do you trust that pharmaceutical patient support programs sufficiently lower costs for patients needing specialty treatments?
